Camurus (CAMX), Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending market authorization of Oczyesa, its octreotide subcutaneous depot, for maintenance therapy in adults with acromegaly who have previously responded to somatostatin analogues.
Fredrik Tiberg, President & CEO of Camurus, noted that Oczyesa's monthly autoinjector pen could improve patient care by maintaining higher octreotide plasma levels and simplifying self-administration.
The CHMP endorsement is supported by a seven-study clinical program, including Phase 3 ACROINNOVA 1 and 2 trials, which demonstrated sustained normalization of insulin-like growth factor-1, symptom reduction, and enhanced quality of life over 52 weeks. Common adverse events included gastrointestinal, nervous system, hepatobiliary, metabolic disorders, and injection site reactions.
A final European Commission decision is expected by mid-2025.
CAMX is currently trading at $59.98 on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.